

Thrombosis and Haemostasis

International Journal
for Vascular Biology and Medicine

Editor-in-Chief:

Klaus T. Preissner, Germany

Deputy Editor-in-Chief (Clinical Studies):

Gregory Y.H. Lip, United Kingdom

Editorial Board:

Charles Abrams, U.S.A.
Marie-Christine Alessi, France
Hellmut Augustin, Germany
Lina Badimon, Spain
Omar Benzakour, France
Francesco Bernardi, Italy
Thomas Bugge, U.S.A.
Raffele de Caterina, Italy
Paul Declerck, Belgium
Carl-Erik Dempfle, Germany
Vincent Ellis, United Kingdom
Bernd Engelmann, Germany
David Gailani, U.S.A.
Pablo Garcia de Frutos, Spain
Samuel Goldhaber, U.S.A.
Regine Heller, Germany
Heiko Herwald, Sweden
Emilio Hirsch, Italy
Kurt Huber, Austria
Shaun Jackson, Australia
Helge Karch, Germany
Nelly Kieffer, China
Thomas Kietzmann, Germany
Steen Dalby Kristensen, Denmark
Irene Lang, Austria
Gregory Y. H. Lip, United Kingdom
Christine Mannhalter, Austria
John McVey, United Kingdom
Leonid Medved, U.S.A.
James Morrissey, U.S.A.
Laszlo Muszbek, Hungary
Frederick Ofori, Canada
Johannes Oldenburg, Germany
Karlheinz Peter, Australia
Thomas Podor, Canada
Curzio Ruegg, Switzerland
Manfred Schmitt, Germany
Wolfgang Siess, Germany
Andrzej Szczeklik, Poland
Mauro Torti, Italy
Victor W. M. van Hinsbergh, The Netherlands
Johannes Waltenberger, The Netherlands
Steve Watson, United Kingdom
Artur-Aron Weber, Germany
Christian Weber, Germany
Jeffrey Weitz, Canada
Johann Wojta, Austria

Index Vol. 101, 2009

Contents

Keywords

Authors

EDITORIAL

Face to face with basic and clinical research in Thrombosis and Haemostasis <i>K. T. Preissner, G. Y. H. Lip</i>	1
---	---

EDITORIAL FOCUS

Dabigatran etexilate for prevention of venous thromboembolism <i>J. E. Eikelboom; J. I. Weitz</i>	2
VTE recurrence in patients with inherited deficiencies of natural anticoagulants <i>F. Dentali; M. Gianni</i>	5
Pulmonary embolism diagnosis: Remember the history and physical exam <i>S. Z. Goldhaber</i>	7
Drug-eluting balloons for percutaneous coronary interventions <i>M. Zimarino; R. De Caterina</i>	9
Another view on prasugrel <i>A. Calatzis</i>	12
Platelet function analysis: At the edge of meaning <i>J. H. Oestreich; S. S. Smyth; C. L. Campbell</i>	217
Thrombin as a common downstream target blocking both platelet and monocyte activation <i>F. Santilli; G. Davì</i>	220
Using kallikrein-related peptidases (KLK) as novel cancer biomarkers <i>M. Schmitt; V. Magdolen</i>	222
Software support for 'doing the right thing right' <i>J. L. Dorsey</i>	413
Atrial fibrillation and stroke risk prevention in real-life clinical practice <i>K. H. Tay; G. Y. H. Lip; D. A. Lane</i>	415
Understanding low INR in clinical practice <i>E. M. Hylek; A. J. Rose</i>	417
Precision and accuracy of CoaguChek S and XS monitors: The need for external quality assessment <i>L. Poller</i>	419
Matrix-Gla protein and vascular calcification: The negative role of oral anticoagulant therapy <i>M. Cozzolino</i>	605
Clopidogrel and proton pump inhibitors: Gastric protection at expense of vascular benefit? <i>V. Serebruany; S. Goto</i>	607
Amniotic fluid embolism: The complication of known pathomechanism but without pathogenetic therapy? <i>M. Uszynski</i>	795

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Methodological issues affecting estimates of bleeding risks and consequences after venous thromboembolism <i>R. J. Glynn</i>	797
Hypergravity and microgravity influence haemostasis <i>R. Gerzer</i>	799
Inflammatory markers for ischaemic stroke <i>R. Pola</i>	800
Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients <i>D. A. Lane; G. Y. H. Lip</i>	802
Prolactin as a modulator of platelet function and thrombosis: The end of the story, or a new beginning? <i>N.-M. Heida; K. Schäfer; S. Konstantinides</i>	991
Viral pathogens as novel activators of procoagulant signalling <i>F. Krötz</i>	993
Direct thrombin inhibitors in patients with mechanical heart valves: Ready for clinical trials? <i>H.-J. Rupprecht</i>	995

VIEWPOINT ARTICLE

Prasugrel development - Claims and achievements <i>V. Serebruany; I. Shalito; O. Kopyleva</i>	14
Future of oral antiplatelet therapy: Four challenged hypotheses <i>V. L. Serebruany; L. M. Makarov</i>	1041

CLINICAL FOCUS

Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting <i>A. Hobson; N. Curzen</i>	23
The 8th American College of Chest Physicians Guidelines – A perspective on venous thromboembolism guidelines <i>A. Squizzato; W. Ageno</i>	31
Heparin-induced thrombocytopenia: What clinicians need to know <i>B. H. Chong; A. Isaacs</i>	279
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? <i>A. T. Cohen; L. Maillardet; Y. Yavin</i>	422
Venous thromboembolism in pregnancy: diagnosis, management and prevention <i>S. D. Chunilal; S. M. Bates</i>	428

THEME ISSUE EDITORIALS

Thrombotic microangiopathies as a prime example for translational medicine <i>P. F. Zipfel</i>	225
---	-----

Cutting edge research for novel therapies of heart and lung diseases <i>T. Braun; K. T. Preissner</i>	610
Recent advances in vascular biology: Selected highlights from IVBM 2008 <i>L. M. Khachigian; K. Peter; M. C. Berndt</i>	997
THEME ISSUE ARTICLES	
Autoantibodies in haemolytic uraemic syndrome (HUS) <i>C. Skerka; M. Józsi; P. F. Zipfel; M.-A. Dragon-Durey; V. Fremeaux-Bacchi</i>	227
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies <i>E. Bresin; S. Gastoldi; E. Daina; D. Belotti; E. Pogliani; P. Perseghin; P. R. Scalzulli; R. Paolini; R. Marcenò; G. Remuzzi; M. Galbusera</i>	233
Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure <i>R. A. Claus; C. L. Bockmeyer, U. Budde; K. Kentouche; M. Sossdorf; T. Hilberg; R. Schneppenheim; K. Reinhart; M. Bauer; F. M. Brunkhorst; W. Lösche</i>	239
Pregnancy-associated thrombotic thrombocytopenic purpura <i>J. Gerth; E. Schleussner; K. Kentouche; M. Busch; M. Seifert; G. Wolf</i>	248
Shiga toxins, glycosphingolipid diversity, and endothelial cell injury <i>J. Müthing; C. H. Schweppe; H. Karch; A. W. Friedrich</i>	252
Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura (TTP) <i>K. Benz; K. Amann</i>	265
Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis <i>C. Licht; V. Fremeaux-Bacchi</i>	271
The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of fibrotic disorders <i>E. C. Keeley; B. Mehrad; R. M. Strieter</i>	613
Role of H ₂ O ₂ -activated TRPM2 calcium channel in oxidant-induced endothelial injury <i>C. M. Hecquet; A. B. Malik</i>	619
Signalling pathways in ischaemic postconditioning <i>D. J. Hausenloy</i>	626
Myocardial protection against reperfusion injury: The cGMP pathway <i>D. Garcia-Dorado; L. Agulló; C. Lluisa Sartorio; M. Ruiz-Meana</i>	635
Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies <i>D. Dragun; A. Philippe; R. Catar; B. Hegner</i>	643
Endothelial adapter proteins in leukocyte transmigration <i>J. D. van Buul; P. L. Hordijk</i>	649
Serine proteases, inhibitors and receptors in renal fibrosis <i>A. A. Eddy</i>	656

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Maturation of blood vessels by haematopoietic stem cells and progenitor cells: Involvement of apelin/APJ and angiopoietin/Tie2 interactions in vessel caliber size regulation <i>N. Takakura; H. Kidoya</i>	999
Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes <i>A. C. Newby; S. J. George; Y. Ismail; J. L. Johnson; G. B. Sala-Newby; A. C. Thomas</i>	1006
Single-chain antibodies as diagnostic tools and therapeutic agents <i>C. E. Hagemeyer; C. von zur Muhlen; D. von Elverfeldt; K. Peter</i>	1012
Talin-dependent integrin signalling in vivo <i>B. G. Petrich</i>	1020
Angiostasis as a way to improve immunotherapy <i>A. W. Griffioen; F. A. Vyth-Dreese</i>	1025
REVIEW ARTICLES	
Compensatory anti-inflammatory response syndrome <i>M. Adib-Conquy; J.-M. Cavailon</i>	36
Biobanks and the search for predictive biomarkers of local and systemic outcome in atherosclerotic disease <i>R. Hurks; W. Peeters; W. J. M. Derksen; W. E. Hellings; I. E. Hofer; F. L. Moll; D. P. V. de Kleijn; G. Pasterkamp</i>	48
The plasma membrane redox system in human platelet functions and platelet-leukocyte interactions <i>D. Del Principe; G. Frega; I. Savini; M. V. Catani; A. Rossi; L. Avigliano</i>	284
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review <i>E. Romualdi; E. Micieli; W. Ageno; A. Squizzato</i>	290
Cell-derived microparticles in haemostasis and vascular medicine <i>L. Burnier; P. Fontana; B. R. Kwak; A. Angelillo-Scherrer</i>	439
The impact of acute and chronic exercise on thrombosis in cardiovascular disease <i>S. L. Bacon; R. Pelletier; K. L. Lavoie</i>	452
Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin <i>C. Rodríguez; M. González-Díez; L. Badimon; J. Martínez-González</i>	665
Prophylaxis in people with haemophilia <i>A. Coppola; M. Franchini; A. Tagliaferri</i>	674
Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update <i>G. M. Rodgers</i>	806
Peripheral arterial disease and Virchow's triad <i>P. C. Bennett; S. H. Silverman; P. S. Gill; G. Y. H. Lip</i>	1032

RAPID AND SHORT COMMUNICATION

Cell-based therapy facilitates venous thrombus resolution <i>S. Di Santo; O. M. Tepper; M. W. von Ballmoos; N. Diehm; J. Völmann; I. Baumgartner; C. Kalka</i>	460
EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction <i>P. Seizer; O. Borst; H. F. Langer; A. Bültmann; G. Münch; Y. Herouy; K. Stellos; B. Krämer; B. Bigalke; B. Büchele; M. G. Bachem; D. Vestweber; T. Simmet; M. Gawaz; A. E. May</i>	682
Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin <i>C. Pettinella; M. Romano; L. Stuppia; F. Santilli; R. Liani; G. Davì</i>	687
Do common prothrombotic mutations influence the risk of cerebral ischaemia in patients with patent foramen ovale? Systematic review and meta-analysis <i>A. Pezzini; M. Grassi; E. Del Zotto; A. Giossi; I. Volonghi; P. Costa; A. Grau; M. Magoni; A. Padovani; C. Lichy</i>	813
VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding <i>G. Spohn; A. Kleinridders; F. T. Wunderlich; M. Watzka; F. Zaucke; K. Blumbach; C. Geisen; E. Seifried; C. Müller; M. Paulsson; J. C. Brüning; J. Oldenburg</i>	1044

ORIGINAL ARTICLES

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C <i>S. Yegneswaran; P. M. Nguyen; A. J. Gale; J. H. Griffin</i>	55
Polymorphisms in the protein C gene as risk factor for venous thrombosis <i>E. R. Pomp; C. J. M. Doggen; H. L. Vos; P. H. Reitsma; F. R. Rosendaal</i>	62
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) <i>A. G. G. Turpie; K. A. Bauer; B. L. Davidson; W. D. Fisher; M. Gent; M. H. Huo; U. Sinha; D. D. Gretler</i>	68
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis <i>S. E. Wolowacz; N. S. Roskell; J. M. Plumb; J. A. Caprinj; B. I. Eriksson</i>	77
Evaluation of enoxaparin dosing requirements in infants and children <i>M. E. Bauman; M. J. Belletrutti; L. Bajzar; K. L. Black; S. Kuhle; M. L. Bauman; M. P. Massicotte</i>	86
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin <i>J.-L. P. Brouwer; W. M. Lijfering; M. K. ten Kate; H. C. Kluin-Nelemans; N. J. G. M. Veeger; J. van der Meer</i>	93
Antiphospholipid antibodies predict imminent vascular events independently from other riskfactors in a prospective cohort <i>C. Neville; J. Rauch; J. Kassis; S. Solymoss; L. Joseph; P. Belisle; J. S. Levine; P. R. Fortin</i>	100

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Microsatellite (GT) _n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions <i>V. Daidone; M. G. Cattini; E. Pontara; F. Sartorello; L. Gallinaro; A. Marotti; C. Scaroni; A. Pagnan; A. Casonato</i>	298
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia <i>A. Molvarec; J. Rigó Jr.; T. Bőze; Z. Derzsy; L. Cervenak; V. Makó; T. Gombos; M. L. Udvardy; J. Hársfalvi; Z. Prohászka</i>	305
Factor XIII-A subunit Val34Leu polymorphism is associated with the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levels <i>G. de la Red; D. Tàssies; G. Espinosa; J. Monteagudo; A. Bové; J. Plaza; R. Cervera; J.-C. Reverter</i>	312
Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: Results from the MONICA/KORA study <i>M. Kolz; J. Baumert; H. Gohlke; H. Grallert; A. Döring; A. Peters; H.-E. Wichmann; W. Koenig; T. Illig</i>	317
How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study <i>C. Hammerstingl; H. Omran; C. Tripp; B. Poetzsch</i>	325
Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia <i>I. M. Wichers; M. W. T. Tanck; J. C. M. Meijers; T. Lisman; P. H. Reitsma; F. R. Rosendaal; H. R. Büller; S. Middeldorp</i>	465
Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels <i>I. Agledahl; E. Brodin; J. Svartberg; J.-B. Hansen</i>	471
Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry <i>Á. Blanco-Molina; J. Trujillo-Santos; R. Tirado; I. Cañas; A. Riera; M. Valdés; M. Monreal</i>	478
Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis <i>V. Roldán; A. Ordoñez; F. Marín; E. Zorio; J. M. Soria; A. Miñano; F. España; R. González-Conejero; J. Pineda; A. Estellés; J. Fontcuberta; V. Vicente; J. Corral</i>	483
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program <i>L. Poller; M. Keown; S. Ibrahim; G. Lowe; M. Moia; A. G. Turpie; C. Roberts; A. M. H. P. van den Besselaar; F. J. M. van der Meer; A. Tripodi; G. Palareti; C. Shiach; S. Bryan; M. Samama; M. Burgess-Wilson; A. Heagerty; P. MacCallum; D. Wright; J. Jespersen</i>	487
The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC) <i>H. A. A. M. van Vliet; S. N. Tchaikovski; F. R. Rosendaal; J. Rosing; F. M. Helmerhorst</i>	691
Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels <i>M. Egi; H. Morimatsu; C. J. Wiedermann; M. Tani; T. Kanazawa; S. Suzuki; T. Matsusaki; K. Shimizu; Y. Toda; T. Iwasaki; K. Morita</i>	696

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification <i>R. Koos; T. Krueger; R. Westenfeld; H. P. Kühl; V. Brandenburg; A. H. Mahnken; S. Stanzel; C. Vermeer; E. C. M. Cranenburg; J. Floege; M. Kelm; L. J. Schurgers</i>	706
Plasma elimination kinetics for factor VII is independent of its activation to factor VIIa and complex formation with plasma inhibitors <i>L. C. Petersen; T. Elm; M. Ezban; T. N. Krogh; D. M. Karpf; A. Steinø; E. H. N. Olsen; B. B. Sørensen</i>	818
In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry <i>K. A. Tanaka; F. Szlam; C. P. Rusconi; J. H. Levy</i>	827
Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains <i>S. Gharagozlou; R. A. Sharifian; J. Khoshnoodi; K. Karimi; M. Milani; D. K. Okita; F. Shokri; B. M. Conti-Fine</i>	834
Coagulation factor XIII serves as protein disulfide isomerase <i>J. Lahav; E. Karniel; Z. Bagoly; V. Sheptovitsky; R. Dardik; A. Inbal</i>	840
Procoagulant activity and phosphatidylserine of amniotic fluid cells <i>J. Zhou; S. Liu; M. Ma; J. Hou; H. Yu; C. Lu; G. E. Gilbert; J. Shi</i>	845
Acquired factor V inhibitor. A problem-based systematic review <i>A. L. Ang; P. Kuperan; C. H. Ng; H. J. Ng</i>	852
Influence of molecular weight of chemically sulfated citrus pectin fractions on their antithrombotic and bleeding effects <i>T. R. Cipriani; A. H. P. Gracher; L. M. de Souza; R. J. C. Fonseca; C. L. R. Belmiro; P. A. J. Gorin; G. L. Sasaki; M. Iacomini</i>	860
A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo <i>W. P. Sheffield; L. J. Eltringham-Smith; S. Gataiance; V. Bhakta</i>	867
Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study <i>F. A. Spencer; J. M. Gore; G. Reed; D. Lessard; L. Pacifico; C. Emery; M. A. Crowther; R. J. Goldberg</i>	878
VIDAS D-dimer in combination with clinical pre-test probability to rule out pulmonary embolism. A systematic review of management outcome studies <i>M. Carrier; M. Righini; R. K. Djurabi; M. V. Huisman; A. Perrier; P. S. Wells; M. Rodger; W. A. Willemin; G. Le Gal</i>	886
In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study <i>G. Gussoni; M. Campanini; M. Silingardi; G. Scannapieco; A. Mazzone; G. Magni; A. Valerio; I. Iori; W. Ageno</i>	893
Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637 <i>J. Deinum; C. Mattsson; T. Inghardt; M. Elg</i>	1051

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes <i>A. Zirlik; S. Ernst; A. Leugers; F. Willecke; B. E. Sobel; C. Bode; T. K. Nordt</i>	1060
Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease <i>Z. Zhou; H. Han; M. A. Cruz; J. A. López; J.-F. Dong; P. Guchhait</i>	1070
Fibrinogen gamma gene 3'-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population <i>S. Uitte de Willige; M. E. Pyle; H. L. Vos; M. C. H. de Visser; C. Lally; Nicole F. Dowling; W. Craig Hooper; Rogier M. Bertina; Harland Austin</i>	1078
Bridging of oral anticoagulation with low-molecular-weight heparin: Experience in 373 patients with renal insufficiency undergoing invasive procedures <i>C. Hammerstingl; H. Omran</i>	1085
Prescription of fondaparinux in hospitalised patients <i>S. Baroletti; M. Labreche; M. Niles; J. Fanikos; S. Z. Goldhaber</i>	1091
Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution <i>H. J. Ng; L. H. Lee</i>	1095
Ankle exercise and venous blood velocity <i>P. D. Stein; A. Y. Yaekoub; S. T. Ahsan; F. Matta; M. M. Lala; B. Mirza; A. Badshah; M. Zamlut; D. J. Malloy; J. E. Denier</i>	1100
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders <i>C. Chi; C. A. Lee; A. England; J. Hingorani; J. Paintsil; R. A Kadir</i>	1104
Venous thromboembolism in nonagenarians. Findings from the RIETE Registry <i>B. Vasco; J. C. Villalba; L. Lopez-Jimenez; C. Falga; J. Montes; J. Trujillo-Santos; M. Monreal</i>	1112

Platelets and Blood Cells

Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability <i>P. C. Wong; E. J. Crain; C. A. Watson; J. Hua; W. A. Schumacher; R. Rehfuss</i>	108
Functional variability of platelet response to clopidogrel correlates with P2Y ₁₂ receptor occupancy <i>C. Bal dit Sollier; N. Berge; B. Boval; L. Hovsepian; L. Drouet</i>	116
Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease <i>T. J. Kunicki; S. A. Williams; D. J. Nugent; P. Harrison; H. C. Segal; A. Syed; P. M. Rothwell</i>	123
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation <i>T. Gremmel; S. Steiner; D. Seidinger; R. Koppensteiner; S. Panzer; C. W. Kopp</i>	333

Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention <i>G. Busch; B. Steppich; D. Sibbing; S.-L. Braun; A. Stein; P. Groha; A. Schömig; A. Kastrati; N. von Beckerath; I. Ott</i>	340
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel <i>D. Sibbing; T. Morath; J. Stegherr; S. Braun; W. Vogt; M. Hadamitzky; A. Schömig; A. Kastrati; N. von Beckerath</i>	714
Stored erythrocytes have less capacity than normal erythrocytes to support primary haemostasis <i>W. H. Reinhart; L. Zehnder; T. Schulzki</i>	720
Effects of microgravity and hypergravity on platelet functions <i>K. Dai; Y. Wang; R. Yan; Q. Shi; Z. Wang; Y. Yuan; H. Cheng; S. Li; Y. Fan; F. Zhuang</i>	902
Influence of platelet count on the expression of platelet collagen receptor glycoprotein VI (GPVI) in patients with acute coronary syndrome <i>B. Bigalke; K. Stellos; D. Stakos; T. Joos; O. Pötz; T. Geisler; C. Bischofs; E. Kremmer; B. F. Krämer; P. Seizer; A. E. May; S. Lindemann; M. Gawaz</i>	911
Prolactin does not affect human platelet aggregation or secretion <i>A. Q. Reuwer; R. Nieuwland; I. Fernandez; V. Goffin; C. M. van Tiel; M. C. L. Schaap; R. J. Berckmans; J. J. P. Kastelein; M. Th. B. Twickler</i>	1119
<i>Wound Healing and Inflammation/Infection</i>	
Risk of venous thromboembolism with rheumatoid arthritis <i>F. Matta; R. Singala; A. Y. Yaekoub; R. Najjar; P. D. Stein</i>	134
Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis <i>A. F. Shorr; M. D. Williams</i>	139
Contribution of (sub)domains of Staphylococcus aureus fibronectin-binding protein to the proinflammatory and procoagulant response of human vascular endothelial cells <i>R. Heying; J. van de Gevel; Y.-A. Que; L. Piroth; P. Moreillon; H. Beekhuizen</i>	495
Levels of inflammatory markers and the development of the post-thrombotic syndrome <i>H. Shbaklo; C. A. Holcroft; S. R. Kahn</i>	505
Modification of the cytoprotective protein C pathway during Dengue virus infection of human endothelial vascular cells <i>C. Cabello-Gutiérrez; M. E. Manjarrez-Zavala; A. Huerta-Zepeda; J. Cime-Castillo; V. Monroy-Martínez; B. Biruete- Correa; B. H. Ruiz-Ordaz</i>	916
Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke <i>G. Licata; A. Tuttolomondo; D. Di Raimondo; S. Corrao; R. Di Sciacca; A. Pinto</i>	929
Role of viral receptors TLR3, RIG-I and MDA5 in mesothelial tissue-type plasminogen activator and plasminogen activator inhibitor-1 synthesis <i>M. Wörnle; M. Sauter; K. Kastenmüller; A. Ribeiro; T. Mussack; R. Ladurner; T. Sitter</i>	1128

Cardiovascular Biology and Cell Signalling

Ischaemic stroke patients with heterozygous factor V Leiden present with multiple brain infarctions and widespread atherothrombotic disease <i>E. Haapaniemi; J. Helenius; D. Jakovljevi; L. Soenne; M. Syrjälä; M. Kaste; R. Lassila; T. Tatlisumak</i>	145
Immature platelets in patients with acute coronary syndromes <i>Erik Lerkevang Grove; Anne-Mette Hvas; Steen Dalby Kristensen</i>	151
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance <i>R. E. Malmström; M. Settergren; F. Böhm; J. Pernow; P. Hjerdahl</i>	157
Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation <i>F. Cesari; F. Sofi; R. Caporale; A. Capalbo; R. Marcucci; C. Macchi; R. Molino Lova; T. Cellai; M. Vannucci; G. F. Gensini; R. Abbate; A. M. Gori</i>	521
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database <i>S. Rietbrock; J. M. Plumb; A. M. Gallagher; T. P. van Staa</i>	527
Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation <i>S. Chia; E. M. Van Cott; O. C. Raffel; I.-K. Jang</i>	535
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1 <i>R. A. Schuepbach; C. Feistritzer; J. A. Fernández; J. H. Griffin; M. Riewald</i>	724
Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction <i>M.-G. Huisse; N. Ajzenberg; L. Feldman; M.-C. Guillin; P. G. Steg</i>	734
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment <i>D. Poli; E. Antonucci; E. Grifoni; R. Abbate; G. F. Gensini; D. Prisco</i>	938
Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels <i>B. Gigante; M. Vikström; L. Strömqvist Meuzelaar; E. Chernogubova; A. Silveira; F. van't Hooft; A. Hamsten; U. de Faire</i>	943

Endothelium and Vascular Biology

Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling <i>R. Madonna; R. De Caterina</i>	345
Cardiovascular Biology and Cell Signalling Association between polymorphisms in the b2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women <i>M. Schürks; T. Kurth; P. M Ridker; J. E. Buring; R. Y. L. Zee</i>	351

Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients <i>E. C. M. Cranenburg; V. M. Brandenburg; C. Vermeer; M. Stenger; G. Mühlenbruch; A. H. Mahnken; U. Gladziwa; M. Ketteler; L. J. Schurgers</i>	359
Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention <i>D. Poli; E. Antonucci; E. Grifoni; R. Abbate; G. F. Gensini; D. Prisco</i>	367
Thrombin inhibits nuclear factor kB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C <i>J.-S. Bae; A. R. Rezaie</i>	513
Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: Kinetics following percutaneous coronary intervention and association with clinical characteristics <i>C. G. Egan; F. Caporali; A. F. Huqi; M. C. Zito; M. Focardi; S. Mondillo; C. Pierli; M. Marzilli; V. Sorrentino</i>	1138
Cellular Proteolysis and Oncology	
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11 <i>H. Thomadaki; K. Mavridis; M. Talieri; A. Scorilas</i>	373
Expression analysis and study of KLK4 in benign and malignant breast tumours <i>G. Papachristopoulou; M. Avgeris; A. Scorilas</i>	381
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis <i>P. Kountourakis; A. Psyrris; A. Scorilas; S. Markakis; D. Kowalski; R. L. Camp; E. P. Diamandis; M. A. Dimopoulos</i>	541
Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation <i>S.-M. Bang; J.-S. Lee; J. Y. Ahn; J. H. Lee; M. S. Hyun; B. S. Kim; M. R. Park; H.-S. Chi; H. Y. Kim; H. J. Kim; M. H. Lee; H. Kim; J. H. Won; H. J. Yoon; D.-y. Oh; E.-M. Nam; S. H. Bae; B.-K. Kim</i>	547
Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer <i>M. Talieri; K. Mathioudaki; P. Prezas; D. K. Alexopoulou; E. P. Diamandis; D. Xynopoulos; A. Ardavanis; N. Arnojiannaki; A. Scorilas</i>	741
Regulation of urokinase receptor function and pericellularproteolysis by the integrin a5b1 <i>R. Bass; V. Ellis</i>	954
Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer <i>K. Haubold; M. Rink; B. Spath; M. Friedrich; F. K.-H. Chun; G. Marx; A. Amirkhosravi; J. L. Francis; C. Bokemeyer; B. Eifrig; F. Langer</i>	1147

Animal Models

Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo <i>I. Scroyen; F. Jacobs; L. Cosemans; B. De Geest; H. R. Lijnen</i>	388
---	-----

Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis
E. Ramacciotti; A. E. Hawley; D. M. Farris; N. E. Ballard; S. K. Wroblewski; D. D. Myers Jr.; P. K. Henke; T. W. Wakefield..... 748

New Technologies, Diagnostic Tools and Drugs

The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution
E. De Smedt; R. Wagenvoord; H. C. Hemker 165

The technique of measuring thrombin generation with fluorescent substrates: 4. The H-transform, a mathematical procedure to obtain thrombin concentrations without external calibration
H. C. Hemker; P. W. Hemker; R. Al Dieri 171

Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices
K. A. Moffat; M. R. Ledford-Kraemer; E. A. Plumhoff; H. McKay; W. L. Nichols; P. Meijer; C. P. Hayward..... 178

Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography
K. Devreese; K. Peerlinck; J. Arnout; M. F. Hoylaerts 185

Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism
R. A. Douma; N. S. Gibson; V. E. A. Gerdes; H. R. Büller; P. S. Wells; A. Perrier; G. Le Gal..... 197

Drug-eluting balloon: Very short-term exposure and overlapping
B. Cremers; U. Speck; N. Kaufels; D. Mahnkopf; M. Kühler; M. Böhm; B. Scheller..... 201

Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study
P. Toulon; Y. Ozier; A. Ankri; M.-H. Fléron; G. Leroux; C. M. Samama 394

Subtherapeutic oral anticoagulant therapy: Frequency and risk factors
E. K. Rombouts; F. R. Rosendaal; F. J. M. van der Meer..... 552

Desmoteplase in acute massive pulmonary thromboembolism
U. Tebbe; P. Bramlage; A. Graf; P. Lechleitner; C. Bode; F.-C. Riess; N. Clemens; Y. Al-Rawi; S. Konstantinides; S. Z. Goldhaber 557

International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy
T. D. Christensen; T. B. Larsen; C. Jensen; M. Maegaard; B. Sørensen..... 563

Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene
I. Corrales; L. Ramirez; C. Altisent; R. Parra; F. Vidal..... 570

Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population
M. Lambert; G. Ferrard-Sasson; S. Dubucquoi; E. Hachulla; L. Prin; P.-Y. Hatron; J. Goudemand; M.-C. Boffa; C. Caron 577

Coagulation assessment by rotation thrombelastometry in normal pregnancy
C. Huissoud; N. Carrabin; M. Benchaib; O. Fontaine; A. Levrat; D. Massignon; S. Touzet; R.-C. Rudigoz; M. Berland..... 755

Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials
F. F. van Doormaal; G. E. Raskob; B. L. Davidson; H. Decousus; A. Gallus; A. W. A. Lensing; F. Piovella; M. H. Prins; H. R. Büller..... 762

Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease
T. Fujimaki; K. Kato; T. Yoshida; M. Oguri; S. Watanabe; N. Metoki; H. Yoshida; K. Satoh; Y. Aoyagi; Y. Nishigaki; M. Tanaka; Y. Nozawa; G. Kimura; Y. Yamada..... 963

Comparative study of accuracy and clinical agreement of the CoaguChek XS portable device versus standard laboratory practice in unexperienced patients
E. G. Torreiro; E. Gómez Fernández; R. Mariño Rodríguez; C. Vázquez López; J. Barreal Núñez..... 969

Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed?
H. M. H. Spronk; A. W. J. H. Dielis; M. Panova-Noeva; R. van Oerle; J. W. P. Govers-Riemslog; K. Hamulyák; A. Falanga; H. Ten Cate 1156

Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Results of an in-vitro study
L. Maegdefessel; T. Linde; T. Michel; K. Hamilton; U. Steinseifer; I. Friedrich; S. Schubert; B. Hauroeder; U. Raaz; M. Buerke; K. Werdan; A. Schlitt..... 1163

CASE REPORTS

Clinical management of thrombosis in inherited factor VII deficiency: A description of two cases
E. Arellano-Rodrigo; M. Gironella; I. Nicolau; M. Vila 402

Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden
N. Rosenzweig; T. Strauss; M. Rubinstein; G. Paret; G. Kenet..... 405

Acquired haemophilia A associated with transitory and severe factor V deficiency during bullous pemphigoid: First report
A. Ryman; T. Hubiche; J. Amiral; A. Taïeb; V. Guerin 582

Myelofibrosis and spinal cord ischaemia
D. Periard; M. Currat; S. D. Qanadli; D. Hayoz; P. Vollenweider..... 584

Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA
M. Stockschröder; L. Ruf; A. Linderer; T. Schroeder; W. T. Knoefel; R. Haas; G. Giers; A. Gerhardt; C. Sucker; R. B. Zotz; R. E. Scharf..... 586

Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of Aa1VS4+1G>T mutation and Aa4841delC truncation (AaPerth)
A. Jayo; E. Arnold; C. González-Manchón; D. Green; S. T. Lord..... 770

Heyde's syndrome without a decrease in large von Willebrand factor multimers: A case of intestinal bleedings reversed by valve replacement in a patient with aortic stenosis <i>A. Undas; J. Windyga; K. Bykowska; P. P. Dimitrow; E. Stepien; J. Sadowski</i>	773
Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function <i>A. Undas; J. Zdziarska; T. Iwaniec; E. Stepien; A. B. Skotnicki; P. de Moerloose; M. Neerman-Arbez</i>	975
First case of protein S deficiency due to a translocation t(3;21)(q11.2;q22) <i>B. Hurtado; M. Nadal; E. Margarit; A. Sánchez; N. Abasolo; N. García; P. Doménech; N. Sala</i>	977

LETTERS TO THE EDITOR

Multiple electrode aggregometry for ex-vivo detection of the anti-platelet effect of non-opioid analgesic drugs <i>C. Jámbar; C. F. Weber; A. Lau; M. Spannagl; B. Zwissler</i>	207
Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia - A prospective family cohort study in asymptomatic subjects <i>A. B. U. Mäkelburg; W. M. Lijfering; S. Middeldorp; K. Hamulyák; N. J. G. M. Veeger; M. H. Prins; H. R. Büller; J. van der Meer</i>	209
Haplotypic or genotypic combinations of three protein Z polymorphisms influence protein Z plasma level <i>V. Le Cam-Duchez; V. Barbay; C. Bal dit Sollier; L. Drouet; M. Coudert; C. Soria; J.-Y. Borg</i>	212
Plasma Gas6 levels and coronary artery disease <i>D. Borgel; E. Durand; S. Clauser; C. Bachelot-Loza; S. Peyrard; V. Remones; M. Aiach; A. Lafont</i>	215
Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor <i>T. Takeda; Y. Sakurai; K. Tatsumi; J. Kato; S. Kasuda; A. Yoshioka; M. Shima</i>	408
An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0 <i>G. Denas; U. Cucchini; S. Illiceto; V. Pengo</i>	410
Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients <i>Z. Verde; C. Santiago; B. Valle; A. Fernández-Santander; F. Bandrés; E. Calvo; J. R. Ruiz; A. Lucía; F. Gómez Gallego</i>	591
Thrombin generation test in patients under anticoagulant therapy with vitamin k antagonists <i>I. Brocal; P. Marco; J. Lucas; J. Verdú; F. Tarín</i>	594
Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities <i>M. R. Taliani; C. Becattini; G. Agnelli; P. Prandoni; M. Moia; M. Bazzan; R. M. Salvi; W. Ageno; G. Guazzaloca; D. Imberti; M. Silingardi; R. Poggio</i>	596
The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis <i>M. Shimizu; S. Nomura; K. Ishii; Y. Mohri; N. Umei; S. Suzuki; Y. Matsuo; A. Isonishi; M. Matsumoto; F. Urase; Y. Maeda; Y. Fujimura</i>	599

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation <i>A. Tveit; A. Bollmann; I. Seljeflot; D. Husser; M. Stridh; L. Sörnmo; H. Arnesen; S. B. Olsson; P. Smith</i>	601
Haemophilia A in two unrelated females due to F8 gene inversions combined with skewed inactivation of X chromosome <i>X. Wang; Y. Lu; Q. Ding; J. Dai; X. Xi; H. Wang</i>	775
Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia <i>S. Hillman; I. Chant; M. Gu; P. Rose; M. Vatish</i>	778
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro <i>X. Jiang; E. J. Crain; J. M. Luetzgen; W. A. Schumacher; P. C. Wong</i>	780
The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins <i>C. T. Ammollo; F. Semeraro; N. Semeraro; M. Colucci</i>	782
Hereditary basis of protein C deficiency (PCD) in thrombosis patients: First report from India <i>N. Pai; S. Shetty; S. Idicula-Thomas; B. Kulkarni; K. Ghosh</i>	785
Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study <i>S. Tondeur; S. Boutruche; C. Biron-Andréani; J.-F. Schved</i>	787
Anti-b2-glycoprotein I ELISA assay: The influence of different antigen preparations <i>A. Cavazzana; V. Pengo; M. Tonello; F. Noventa; C. Grossi; M. O. Borghi; P. de Moerloose; G. Reber; A. Ruffatti</i>	789
More on thromboprophylaxis: Quantifying risk for venous thromboembolism <i>R. Arya; S. Paneesha; A. McManus; N. Parsons; N. Scriven; T. Farren; T. Nokes; H. Smith; D. O'Shaughnessy; P. Rose</i>	791
Two novel mutations at contiguous codons in the fibrinogen Bb chain associated with hypofibrinogenaemia <i>R. L. Davis; S. May; S. Chunilal; S. O. Brennan</i>	980
Endothelial progenitor cells are selectively mobilised immediately after coronary artery bypass grafting or valve surgery <i>D. M. Smadja; A. Godier; S. Susen; R. R. S. Packard; J.-N. Fabiani; M. Aiach; P. Gaussem</i>	983
Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin <i>I. Gouin-Thibault; M. M. Samama</i>	986
Evaluation of the CoaguChek XS Plus system in a Swiss community setting <i>A. Deom; G. Reber; D. A. Tsakiris; F.-M. Hannes; W. Plesch</i>	988
Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer <i>K. Matsue; K. Matsuo; H. Fujiwara; K.-i. Iwama; B. Y. Hayama; S. Kimura; M. Yamakura; M. Takeuch</i>	1170

CONTENTS – Thrombosis and Haemostasis 2009; 101 (1-6)

Long-term stability of coagulation variables: Protein S as a biomarker for preanalytical storage-related variations in human plasma <i>F. Betsou; B. Rousset; N. Guillaume; J.-J. Lefrère</i>	1172
Cardiac biomarkers levels predict pulmonary embolism extent on chest computed tomography and prognosis in non-massive pulmonary embolism <i>N. Vuilleumier; A. Perrier; J.-C. Sanchez; N. Turck; G. Le Gal; F. Verschuren; D. Gruson; N. Mensi; D. Hochstrasser; M. Righini</i>	1176

KEYWORDS – Thrombosis and Haemostasis 2009; 101 (1-6)

- α1-adrenergic receptor (α1 AR)** 643
α2-adrenergic receptor gene..... 351
α2-glycoprotein I 185
(GT)n locus 298
- Acenocumarol**..... 969
Acquired coagulation disorders..... 852
Activated clotting time 535
Activated protein C..... 55, 724
Activated protein C resistance . 100, 691
Acute coronary syndrome 911
Acute myocardial infarction..... 635
ADAMTS 13233,239,248,305
ADAMTS 13 activity 1070
Adherence..... 422
Adhesion molecules 505, 1025
Adhesion receptors 649, 1020
Adipocyte 1060
Adipogenesis 388
ADP..... 157
Advanced ovarian cancer..... 541
African-Americans..... 1078
Alpha2-macroglobulin 818
Alteplase 557
Amniotic fluid cells..... 845
Angiogenesis and inhibitors 1025
Angiogenesis-1 999
Angiotensin II type 1 receptor 643
Animal models 748
Ankle exercise..... 1100
Anti-beta2-glycoprotein I 100
Anti-factor Xa activity 325
Anti-factor Xa levels 86
Antibodies 185
Antibody fragments 1012
Anticoagulant
.....77, 290, 422, 483, 762, 860
Anticoagulant stability 552
Anticoagulation86, 827, 1085, 1163
Antioxidant vitamins 284
Antiphospholipid antibodies 100, 312
Antiphospholipid autoantibodies 577
Antiplatelet agents..... 14, 333
Antithrombin.....340, 535, 696, 806, 818
Antithrombotic 860
Antithrombotic agents 1091
Aortic valve calcification 706
APC.....916
Apelin..... 999
APJ 999
Aptamer 827
AQUA..... 541
Argatroban 1163
Arterial thrombosis 151, 1032
Asians 1095
Aspirin..... 123
Aspirin resistance..... 151, 687
Atherosclerosis48, 682, 1006
Atherothrombosis
..... 14, 151, 943, 1006, 1119
Atrial fibrillation..... 367, 938
Autoantibodies 233, 643
Autoimmune diseases..... 227
Automated DNA sequencing..... 570
- Bacterial infection**..... 495
Balloon angioplasty 1138
Betrixaban 68
Biacore..... 1051
Biobank 48
Biomarker..... 48, 381
Bivalirudin..... 1163
Bleeding 547, 674, 878, 1085
Bleeding phenotype..... 1044
Bone phenotype 1044
Breast cancer 381
Bridging 325, 1085
- C3 deposition** 271
C3 deposition glomerulopathy (C3DG)271
Calcification 359
Calibrated automated thrombogram1156
Calibration 171
Cancer..... 762, 1147
Carboplatin..... 373
Cardiac catheterisation..... 535
Cardiac rehabilitation..... 521
Cardiovascular disease 145
Case-control study 62
Cell adhesion..... 513, 954
Cell lines 741
Cell therapy 460
Cerebral bleeding 290
Cerebral infarct..... 929
Cerebrovascular accident..... 929
Cerebrovascular disease..... 929
Chemokines 613
Children 86, 674
Chronic kidney disease 963
Citrus pectin 860
Clearance 818
Clinical decision rule..... 197
Clinical events 487
Clinical studies 1032
Clinical trials 14, 68
Clopidogrel 108, 116, 714
CoaguChek XS..... 969
Coagulation 145,394, 452, 916
Coagulation factors 465
Coagulation inhibitors 178
Collagens 613
Colorectal cancer 741
Complement system..... 271
Complex formation 818
Computer-dosage..... 487
Contraceptives 478
Corn trypsin inhibitor 1156
Coronary artery disease 1138
Coumarins 563
CXCR4 1138
Cytochemokines..... 521
Cytokine 36, 929, 943
Cytoprotection 916
Cytotoxic drugs..... 373
- D-dimer** 197, 886
DAWN AC 487
Deep venous thrombosis.....
..... 134, 139, 465, 505, 893, 1100
Dengue virus 916
- Dense deposit disease (DDD)**265
Desmoteplase.....557
Diagnosis..... 197, 886
Dialysis 359
Diluted viper venom time577
Direct factor Xa inhibitor 68
Disseminated intravascular coagulation696
Dosage/adverse effects86
Dose frequency422
Doxorubicin.....373
Drug-eluting balloon.....201
- Economy class syndrome**..... 1100
Ectosome.....439
Elderly..... 1112
Embolism..... 77
EMMPRIN.....682
Endothelial activation.....345
Endothelial cells.....
..... 252, 495, 619, 649, 724, 916
Endothelial progenitor cells.....
..... 460, 521, 1138
Endotoxin..... 36
Enoxaparin 86, 1085
Enzyme kinetics..... 1051
EPCR.....513
EPCR inflammation 916
Epidemiological studies 527, 943
Epidemiology 93, 878
Epitope mapping.....834
Erythrocyte 720
Etoposide.....373
Exercise.....452
Exercise capacity..... 521
Extracellular haemoglobin 1070
Extracellular matrix 1006
Ezetimibe..... 157
- Factor H (CFH)**271
Factor IXa inhibition.....827
Factor V inhibitors.....852
Factor V Leiden mutation..... 145
Factor Va 55
Factor VIIa 818
Factor VIII inhibitor.....834
Factor XIII 840
Factor XIII polymorphism.....312
Familial thrombosis.....465
Female gender 938
Fibrate 1060
Fibrinogen..... 312, 317
Fibrinogen gamma..... 1078
Fibrinolysis..... 452, 734, 867
Fibrosis..... 656
Fluorogenic methods 165, 171
Fondaparinux..... 1091
Fresh frozen plasma.....394
FVIII..... 834
- Gb3Cer**252
Genetics 317, 483, 963
Gla-domain proteins 359
Glomerulonephritis C3 (GNC3).....271
Glycoprotein VI.....911

KEYWORDS – Thrombosis and Haemostasis 2009; 101 (1-6)

GPVI	682	Linkage disequilibrium.....	298	Plaque signature.....	48
Haematopoietic progenitor cells.....	999	Low-molecular-weight heparin (LMWH)		Plasma coagulation	1051
Haematopoietic stem cell	999	325, 428, 1085	Plasma membrane redox system	284
Haemolytic uremic syndrome (HUS)	265, 271	Lupus anticoagulant	178, 185	Plasmapheresis	248
Haemophilia	674	Lysis	557	Plasmin.....	867
Haemophilia A.....	834	Macrophages	460	Plasminogen.....	748
Haemorrhage.....	394, 878, 902	Major bleed.....	68	Plasminogen activation.....	954
Haemostasis	108, 439, 720,852, 1060	MALDITOF- MS.....	252	Plasminogen activator inhibitor-1.....	656
Haplotypes	317	Management of disease	852, 893	Platelet activation	157, 1119
Heart valve thrombosis	1163	Management study.....	886	108, 333, 714, 720, 1119
HELLP syndrome.....	305	Massive pulmonary embolism	557	Platelet count.....	911
Hemostasis	691	Matrix Gla protein	359, 706	Platelet function tests.....	333
Heparin	139, 535, 762	Matrix metalloproteinases	1006	Platelet pharmacology	340
Heparin-induced thrombocytopenia	1091	MDA5	1128	Platelet physiology.....	635
Hereditary antithrombin deficiency...	806	Mechanical heart valve.....	290	Platelets... 116, 123, 239, 284, 452, 682,	720, 902
High-density lipoproteins	665	Membranoproliferative glomerulonephritis		Point of care	394
Hirudin.....	867	(MPGN)	265, 271	Point-of-care testing.....	563
Human stratum corneum chymotryptic		Men	471	Polymorphism... 62, 351, 687, 963, 1078	
enzyme	741	Mesothelial.....	1128	Popliteal vein	1100
Hypercoagulability.....	465, 755	Meta-analysis	77	Post-thrombotic syndrome.....	505
Hypergravity	902	Metabolic syndrome	1060	Prasugrel	108
Hypertension.....	317	Microparticle.....	439, 748, 1147	Predictability	696
Idraparinux	422	Microparticle-linked tissue factor	734	Predictive value of tests.....	886
Imaging	706, 1012	Miller Index.....	557	Preeclampsia.....	305
Immunity	36,227, 1025	Mitochondrial permeability transition pore		Pregnancy	248, 305, 428, 755
Inactivation.....	55	626	Prevalence.....	1095
Infants	86	Mitoxantrone.....	373	Prevention	139, 367, 478
Infection	36	Molecular diagnosis.....	570	Procoagulant activity.....	845
Inflammation		Monocyte.....	36	Prognosis.....	381, 541
.....	495, 505, 649, 748, 929, 1006, 1012	Mutation analysis.....	570	Prolactin.....	1119
Inflation time.....	201	Myeloproliferative disorders.....	547	Prolactin receptor	1119
Inherited coagulation disorders	1104	Myocardial infarction	151, 351, 483, 626, 734, 943, 963	Prophylaxis	77, 674, 893
Inhibition.....	55	NAD(P)H oxidase	284	Prostacyclin	665
INR	552, 969	Neovascularisation	460	Prostate cancer	373
Insulin.....	345	Neutrophil.....	36	Protease-activated receptor- 1	724
Insulin resistance	345	NF- α B.....	513	Protein C.....	62,513
Integrins	954, 1020	Nitric oxide.....	665	Protein function.....	706
Interleukins.....	505	Obesity	388	Protein kinases	626
International normalised ratio	563	Oral anticoagulant	68, 367, 552, 563	Prothrombin	55, 185
International Society on Thrombosis and		Oral anticoagulation	325, 706, 969	Prothrombotic disorders.....	813
Haemostasis	696	Organ failure.....	239	Proton pump inhibitors.....	714
Intrauterine device	691	Outcome.....	1112	Pulmonary artery pressure	557
Ischaemic heart disease	635	Overlap.....	201	Pulmonary embolism	
Ischaemic postconditioning.....	626	Oxidative stress.....	619	134, 139, 197, 893, 1100
Ischaemic stroke	145, 351	Paclitaxel	201	Quality of anticoagulation	938
ISTH guidelines.....	178	PAI-1	388, 1060, 1128	Quality of life.....	674
Janus kinase 2.....	547	PAR-1	513, 916	Rare diseases.....	233
Kallikrein-related peptidase 8.....	541	Patent foramen ovale	813	Recurrent venous thromboembolism..	93
Kallikrein-related peptidases	373	Pathology	265	Regional analgesia	1104
Kallikreins.....	373, 381	PC3	373	Register	1085
KLK4	381	PDI	840	Reperfusion injury.....	626
KLK5	373	Pentasaccharides.....	762	Restenosis	201
KLK7	741	Percutaneous coronary intervention	1138	Rheumatoid arthritis.....	134
KLK11	373	Perioperative management	1085	Rho	513
Knockout mouse	1044	Peripheral arterial occlusive disease	145	RIG-I	1128
Labour pain relief	1104	PFA-100	123	Risk	1078
Lactadherin	845	Phagedisplay.....	1012	Risk factors..... 62, 483, 527, 929, 1032	
Leukocyte function/ activation	340	Pharmacogenetics.....	687	Rituximab.....	233
Leukocyte trafficking / recruitment... 649		Phosphatidylserine.....	845	Safety	487
		Phospholipid antibodies	178	Sample dilution	165

KEYWORDS – Thrombosis and Haemostasis 2009; 101 (1-6)

Self-management.....	563, 969	Urokinase receptor (uPAR)	656
Sepsis	139, 239, 724	Validation.....	696
Sickle cell disease.....	1070	Variability of response	116
Signal transduction.....	649	Vascular barrier.....	724
Simulated microgravity.....	902	Vascular cell adhesion molecule-1 ...	345
Simvastatin	157	Vascular function.....	665
SNP	123	Vascular pathologies	439
Sphingosine-1-phosphate	665	Venous blood velocity	1100
STEC	252	Venous thromboembolism (VTE)	
Stratification	1085	. 134, 428, 478, 762, 806, 886, 878,	
Stroke.....	367, 813, 929, 938	1078, 1112	
Stroke prevention.....	527	Venous thrombosis.....	
Sulfated polysaccharide.....	860 62, 68, 460, 465, 691, 748, 1095	
Surgery	394, 1085	Vitamin K.....	359, 1044
Systemic inflammation	239	VKORC1.....	1044
T-PA	557	Von Willebrand disease.....	570
Testing	394	Von Willebrand factor	
Testosterone	471 100, 248, 298, 305, 570, 1070	
TFPI	471	Vulnerable plaque	48
Thrombelastography	755	VWF	123
Thrombelastometry	755	VWF level variability	298
Thrombin.....	157, 513, 734, 867, 943	VWF promoter SNPs.....	298
Thrombin generation		Warfarin	367, 487, 938
.....	165, 171, 471, 1156	Wells rule.....	197
Thrombin inhibition.....	827	Wound healing	613
Thrombin inhibitor	1051	Young	813
Thrombocytic thrombopenic purpura (TTP)			
.....	265		
Thrombocytopenia	227, 248		
Thromboembolism	422		
Thrombomodulin	916		
Thrombophilia	93, 428		
Thrombopoiesis	151		
Thromboprophylaxis.....	806		
Thrombosis			
....	77, 100, 108, 185, 227, 312, 483,		
495, 547, 867, 902, 1012, 1020, 1085			
Thrombotic microangiopathy (TMA) 239,			
265			
Thrombotic thrombocytopenic			
purpura(TTP / HUS).....	227, 248		
Tie2	999		
Tissue factor	748		
Tissue factor / factor VII	495		
Tissue factor / factor VIIa	1147		
Tissue factor activity.....	748		
TLC overlay assay	252		
TMA-index.....	239		
Toll-like receptor 3.....	1128		
Total knee replacement (TKR)	68		
Total pulmonary resistance	557		
Transfusion	394, 720		
Transglutaminase.....	840		
TRPM2.....	619		
TTP	233		
Tumor markers.....	741		
Two-hit model	36		
Type 2 diabetes	345		
Ubiquinone	284		
Unfractionated heparin.....	1163		
UPA.....	954		
UPAR	954		
Urokinase.....	656		

AUTHORS – Thrombosis and Haemostasis 2009; 101 (1-6)

Abasolo N.	977	Bennett, P.C.	1032	Caporali, F.	1138
Abbate R.	367, 521, 938	Benz, K.	265	Caprini, J.A.	77
Adib-Conquy, M.	36	Berckmans, R.J.	1119	Carles Villalba, J.	1112
Ageno, W.	31, 290, 596, 893	Berge, N.	116	Caron, C.	577
Agledahl, I.	471	Berland, M.	755	Carrabin, N.	755
Agnelli, G.	596	Berndt, M.C.	997	Carrier, M.	886
Agulló, L.	635	Bertil, Olsson S.	601	Casonato, A.	298
Ahsan, S.T.	1100	Bertina, R.M.	1078	Catani, M.V.	284
Aiach, M.	215, 983	Betsou, F.	1172	Catar, R.	643
Ajzenberg, N.	734	Bhakta, V.	867	Cavaillon, J.-M.	36
Al Dieri, R.	171	Bigalke, B.	682, 911	Cavazzana, A.	789
Al-Rawi, Y.	557	Biron-Andréani, C.	V787	Cañas, I.	478
Alexopoulou, D.K.	741	Biruete-Correa, B.	916	Cellai, T.	521
Altisent, C.	570	Bischofs, C.	911	Cervenak, L.	305
Amann, K.	265	Black, K.L.	86	Cervera, R.	312
Amiral, J.	582	Blanco-Molina, Á.	478	Cesari, F.	521
Amirkhosravi, A.	1147	Blumbach, K.	1044	Chant, I.	778
Ammollo, C.T.	782	Bockmeyer, C.L.	239	Cheng, H.	902
Ang, A.L.	852	Bode, C.	557, 1060	Chernogubova, E.	943
Angelillo-Scherrer, A.	439	Boffa, M.-C.	577	Chi, C.	1104
Ankri, A. 394		Bokemeyer, C.	1147	Chi, H.-S.	547
Antonucci, E.	367, 938	Bollmann, A.	601	Chia, S.	535
Aoyagi, Y.	963	Borg, J.-Y.	212	Chong, B.H.	279
Ardavanis, A.	741	Borgel, D.	215	Christensen, T.D.	563
Arellano-Rodrigo, E.	402	Borst, O.	682	Chunilal, S.	980
Arnesen, H.	601	Boutruche, S.	V787	Chunilal, S.D.	428
Arnogiannaki, N.	741	Boval, B.	116	Cime-Castillo, J.	916
Arnold, E.	770	Bové, A.	312	Cipriani, T.R.	860
Arnout, J.	185	Bramlage, P.	557	Claus, R.A.	239
Arya, R.	791	Brandenburg, V.	706	Clauser, S.	215
Austin, H.	1078	Brandenburg, V.M.	359	Clemens, N.	557
Avgeris, M.	381	Braun, S.	714	Cohen, A.T.	422
Avigliano, L.	284	Braun, S.-L.	340	Colucci, M.	782
		Braun, T.	610	Conti-Fine, B.M.	834
Bachelot-Loza, C.	215	Brennan, S.O.	980	Coppola, A.	674
Bachem, M.G.	682	Bresin, E.	233	Corral, J.	483
Bacon, S.L.	452	Brocal, I.	594	Corrales, I.	570
Badimon, L.	665	Brodin, E.	471	Corrao, S.	929
Badshah, A.	1100	Brouwer, J.-L.P.	93	Cosemans, L.	388
Bae, J.-S.	513	Brunkhorst, F.M.	239	Costa, P.	813
Bagoly, Z.	840	Bryan, S.	487	Coudert, M.	212
Bajzar, L.	86	Brüning, J.C.	1044	Cozzolino, M.	605
Bal dit Sollier, C.	116, 212	Budde, U.	239	Craig Hooper, W.	1078
Ballard, N.E.	748	Buerke, M.	1163	Crain, E.J.	108, 780
Bandrés, F.	591	Burgess-Wilson, M.	487	Cranenburg, E.C.M.	359, 706
Bang, S.-M.	547	Buring, J.E.	351	Cremers, B.	201
Barbay, V.	212	Burnier, L.	439	Crowther, M.A.	878
Baroletti, S.	1091	Busch, G.	340	Cruz, M.A.	1070
Barreal Núñez, J.	969	Busch, M.	248	Cucchini, U.	410
Bass, R.	954	Bykowska, K.	773	Curat, M.	584
Bates, S.M.	428	Böze, T.	305	Curzen, N.	23
Bauer, K.A.	68	Böhm, F.	157		
Bauer, M.	239	Böhm, M.	201	Dai, J.	775
Bauman, M.E.	86	Büchele, B.	682	Dai, K.	902
Bauman, M.L.	86	Büller, H.R.	197, 209, 465, 762	Daidone, V.	298
Baumert, J.	317	Bültmann, A.	682	Daina, E.	233
Baumgartner, I.	460			Dalby Kristensen, S.	151
Bazzan, M.	596	Cabello-Gutiérrez, C.	916	Dardik, R.	840
Becattini, C.	596	Calatzis, A.	12	Davidson, B.L.	68, 762
Beekhuizen, H.	495	Calvo, E.	591	Davis, R.L.	980
Belisle, P.	100	Camp, R.L.	541	Davì, G.	220, 687
Belletrutti, M.J.	86	Campanini, M.	893	De Caterina, R.	9, 345
Belmiro, C.L.R.	860	Campbell, C.L.	217	de Faire, U.	943
Belotti, D.	233	Capalbo, A.	521	De Geest, B.	388
Benchaib, M.	755	Caporale, R.	521	de Kleijn, D.P.V.	48

AUTHORS – Thrombosis and Haemostasis 2009; 101 (1-6)

de la Red, G.....	312	Farren, T.....	791	Gombos, T.....	305
de Moerloose, P.....	789, 975	Farris, D.M.....	748	González-Conejero, R.....	483
De Smedt, E.....	165	Feistritzer, C.....	724	González-Díez, M.....	665
de Souza, L.M.....	860	Feldman, L.....	734	González-Manchón, C.....	770
de Visser, M.C.H.....	1078	Fernandez, I.....	1119	Gore, J.M.....	878
Decousus, H.....	762	Fernández, J.A.....	724	Gori, A.M.....	521
Deinum, J.....	1051	Fernández-Santander, A.....	591	Gorin, P.A.J.....	860
Del Principe, D.....	284	Ferrard-Sasson, G.....	577	Goto, S.....	607
Del Zotto, E.....	813	Fisher, W.D.....	68	Goudemand, J.....	577
Denas, G.....	410	Floege, J.....	706	Gouin-Thibault, I.....	986
Denier, J. E.....	1100	Fléron, M.-H.....	394	Govers-Riemslog, J.W.P.....	1156
Dentali, F.....	5	Focardi, M.....	1138	Gracher, A.H.P.....	860
Deom, A.....	988	Fonseca, R.J.C.....	860	Graf, A.....	557
Derksen, W.J.M.....	48	Fontaine, O.....	755	Grallert, H.....	317
Derzsy, Z.....	305	Fontana, P.....	439	Grassi, M.....	813
Devreese, K.....	185	Fontcuberta, J.....	483	Grau, A.....	813
Di Raimondo, D.....	929	Fortin, P.R.....	100	Grazia Cattini, M.....	298
Di Santo, S.....	460	Franchini, M.....	674	Green, D.....	770
Di Sciacca, R.....	929	Francis, J.L.....	1147	Gremmel, T.....	333
Diamandis, E.P.....	541, 741	Frega, G.....	284	Gretler, D.D.....	68
Diehm, N.....	460	Fremaux-Bacchi, V.....	227, 271	Griffin, J.H.....	55, 724
Dielis, A.W.J.H.....	1156	Friedrich, I.....	1163	Griffioen, A.W.....	1025
Dimitrow, P.P.....	773	Friedrich, M.....	1147	Grifoni, E.....	367, 938
Dimopoulos, M.A.....	541	Friedrich, A.W.....	252	Groha, P.....	340
Dine Qanadli, S.....	584	Fujimaki, T.....	963	Grossi, C.....	789
Ding, Q.....	775	Fujimura, Y.....	599	Gruson, D.....	1176
Djurabi, R.K.....	886	Fujiwara, H.....	1170	Gu, M.....	778
Doggen, C.J.M.....	62	Galbusera, M.....	233	Guazzaloca, G.....	596
Doménech, P.....	977	Gale, A.J.....	55	Guchhait, P.....	1070
Dong, J.-F.....	1070	Gallagher, A.M.....	527	Guerin, V.....	582
Doolittle, R.F.....	1179	Gallinaro, L.....	298	Guillaume, N.....	1172
Dorsey, J.L.....	413	Gallus, A.....	762	Guillin, M.-C.....	734
Douma, R.A.....	197	García-Dorado, D.....	635	Gussoni, G.....	893
Dowling, N.F.....	1078	García, N.....	977	Gómez Fernández, E.....	969
Dragon-Durey, M.-A.....	227	Gastoldi, S.....	233	Gómez Gallego, F.....	591
Dragun, D.....	643	Gataiance, S.....	867	Haapaniemi, E.....	145
Drouet, L.....	116, 212	Gaussem, P.....	983	Haas, R.....	586
Dubucquoi, S.....	577	Gawaz, M.....	682, 911	Hachulla, E.....	577
Durand, E.....	215	Geisen, C.....	1044	Hadamitzky, M.....	714
Döring, A.....	317	Geisler, T.....	911	Hagemeyer, C.E.....	1012
Eddy, A.A.....	656	Gensini, G.F.....	367, 521, 938	Hamilton, K.....	1163
Egan, C.G.....	1138	Gent, M.....	68	Hammerstingl, C.....	325, 1085
Egi, M.....	696	George, S.J.....	1006	Hamsten, A.....	943
Eifrig, B.....	1147	Gerdes, V.E.A.....	197	Hamulyák, K.....	209, 1156
Eikelboom, J.E.....	2	Gerhardt, A.....	586	Han, H.....	1070
Elg, M.....	1051	Gerth, J.....	248	Hannes, F.-M.....	988
Ellis, V.....	954	Gerzer, R.....	799	Hansen, J.-B.....	471
Elm, T.....	818	Gharagozlou, S.....	834	Harrison, P.....	123
Eltringham-Smith, L.J.....	867	Ghosh, K.....	785	Hatron, P.-Y.....	577
Emery, C.....	878	Gianni, M.....	5	Haubold, K.....	1147
England, A.....	1104	Gibson, N.S.....	197	Hauroeder, B.....	1163
Eriksson, B.I.....	77	Giers, G.....	586	Hausenloy, D.J.....	626
Ernst, S.....	1060	Gigante, B.....	943	Hawley, A.E.....	748
España, F.....	483	Gilbert, G.E.....	845	Hayama, B.Y.....	1170
Espinosa, G.....	312	Gill, P.S.....	1032	Hayoz, D.....	584
Estellés, A.....	483	Giossi, A.....	813	Hayward, C.P.....	178
Eugenia Manjarrez-Zavala, M.....	916	Gironella, M.....	402	Heagerty, A.....	487
Ezban, M.....	818	Gladziwa, U.....	359	Hecquet, C.M.....	619
Fabiani, J.-N.....	983	Glynn, R.J.....	797	Hegner, B.....	643
Falanga, A.....	1156	Godier, A.....	983	Heida, N.-M.....	991
Falga, C.....	1112	Goffin, V.....	1119	Helenius, J.....	145
Fan, Y.....	902	Gohlke, H.....	317	Hellings, W.E.....	48
Fanikos, J.....	1091	Goldberg, R.J.....	878	Helmerhorst, F.M.....	691
		Goldhaber, S.Z.....	7, 557, 1091	Hemker, H.C.....	165, 171

AUTHORS – Thrombosis and Haemostasis 2009; 101 (1-6)

Hemker, P.W.....	171	Joseph, L.....	100	Lafont, A.....	215
Heng Lee, L.....	1095	Jung Kim, H.....	547	Lahav, J.....	840
Henke, P.K.....	748	Jámbor, C.....	207	Lala, M.M.....	1100
Herouy, Y.....	682	Józsi, M.....	227	Lally, C.....	1078
Heying, R.....	495	Kadir, R.A.....	1104	Lambert, M.....	577
Hilberg, T.....	239	Kahn, S.R.....	505	Lane, D.A.....	415, 802
Hillman, S.....	778	Kalka, C.....	460	Langer, F.....	1147
Hingorani, J.....	1104	Kanazawa, T.....	696	Langer, H.F.....	682
Hjemdahl, P.....	157	Karch, H.....	252	Larsen, T.B.....	563
Ho Won, J.....	547	Karimi, K.....	834	Lassila, R.....	145
Hobson, A.....	23	Karniel, E.....	840	Lau, A.....	207
Hochstrasser, D.....	1176	Karpf, D.M.....	818	Lavoie, K.L.....	452
Hofer, I.E.....	48	Kassis, J.....	100	Le Cam-Duchez, V.....	212
Holcroft, C.A.....	505	Kaste, M.....	145	Le Gal, G.....	197, 886, 1176
Hoon Lee, J.....	547	Kastelein, J.J.P.....	1119	Lechleitner, P.....	557
Hoon Tay, K.....	415	Kastenmüller, K.....	1128	Ledford-Kraemer, M.R.....	178
Hordijk, P.L.....	649	Kastrati, A.....	340, 714	Lee, J.-S.....	547
Hou, J.....	845	Kasuda, S.....	408	Lee, M.H.....	547
Hovsepian, L.....	116	Kato, K.....	963	Lee, C.A.....	1104
Hoylaerts, M.F.....	185	Kato, J.....	408	Lefrère, J.-J.....	1172
Hua, J.....	108	Kaufels, N.....	201	Lensing, A.W.A.....	762
Hubiche, T.....	582	Keeley, E.C.....	613	Lerkevang Grove, E.....	151
Huerta-Zepeda, A.....	916	Kelm, M.....	706	Leroux, G.....	394
Huisman, M.V.....	886	Kenet, G.....	405	Lessard, D.....	878
Huisse, M.-G.....	734	Kentouche, K.....	239, 248	Leugers, A.....	1060
Huissoud, C.....	755	Keown, M.....	487	Levine, J.S.....	100
Huo, M.H.....	68	Ketteler, M.....	359	Levrat, A.....	755
Huqi, A.F.....	1138	Khachigian, L.M.....	997	Levy, J.H.....	827
Hurks, R.....	48	Khoshnoodi, J.....	834	Li, S.....	902
Hurtado, B.....	977	Kidoya, H.....	999	Liani, R.....	687
Husser, D.....	601	Kim, H.....	547	Licata, G.....	929
Hvas, A.-M.....	151	Kim, B.-K.....	547	Licht, C.....	271
Hwa Bae, S.....	547	Kimura, G.....	963	Lichy, C.....	813
Hylek, E.M.....	417	Kimura, S.....	1170	Lijfering, W.M.....	93, 209
Hyun, M.S.....	547	Kleinridders, A.....	1044	Lijnen, H.R.....	388
Hársfalvi, J.....	305	Kluin-Nelemans, H.C.....	93	Linde, T.....	1163
Iacomini, M.....	860	Knoefel, W.T.....	586	Lindemann, S.....	911
Ibrahim, S.....	487	Koenig, W.....	317	Linderer, A.....	586
Ilicula-Thomas, S.....	785	Kolz, M.....	317	Lip, G.Y.H.....	1, 415, 802, 1032
Iliceto, S.....	410	Konstantinides, S.....	557, 991	Lisman, T.....	465
Illig, T.....	317	Koos, R.....	706	Liu, S.....	845
Imberti, D.....	596	Kopp, C.W.....	333	Lluisa Sartorio, C.....	635
Inbal, A.....	840	Koppensteiner, R.....	333	Lopez-Jimenez, L.....	1112
Inghardt, T.....	1051	Kopyleva, O.....	14	Lord, S.T.....	770
Iori, I.....	893	Kountourakis, P.....	541	Lowe, G.....	487
Isaacs, A.....	279	Kowalski, D.....	541	Lu, Y.....	775
Ishii, K.....	599	Kremmer, E.....	911	Lu, C.....	845
Ismail, Y.....	1006	Krogh, T.N.....	818	Lucas, J.....	594
Isonishi, A.....	599	Krueger, T.....	706	Lucía, A.....	591
Iwama, K.....	1170	Krämer, B.....	682	Luetgen, J.M.....	780
Iwaniec, T.....	975	Krämer, B.F.....	911	López, J.A.....	1070
Iwasaki, T.....	696	Krötz, F.....	993	Lösche, W.....	239
Jacobs, F.....	388	Kuhle, S.....	86	Ma, M.....	845
Jakovljeviã, D.....	145	Kulkarni, B.....	785	MacCallum, P.....	487
Jang, I.-K.....	535	Kunicki, T.J.....	123	Macchi, C.....	521
Jayo, A.....	770	Kuperan, P.....	852	Madonna, R.....	345
Jensen, C.....	563	Kurth, T.....	351	Maeda, Y.....	599
Jespersen, J.....	487	Kwak, B.R.....	439	Maegaard, M.....	563
Jiang, X.....	780	Kyoung-Hwan Chun, F.....	1147	Maegdefessel, L.....	1163
Johnson, J.L.....	1006	Kühl, H.P.....	706	Magdolen, V.....	222
Joo Ng, H.....	852, 1095	Kühler, M.....	201	Magni, G.....	893
Joong Yoon, H.....	547	Labreche, M.....	1091	Magoni, M.....	813
Joos, T.....	911	Ladurner, R.....	1128	Mahnken, A.H.....	359, 706
				Mahnkopf, D.....	201

Maillardet, L.	422	Müthing, J.	252	Pettinella, C.	687
Makarov, L.M.	1041	Nadal, M.	977	Peyrard, S.	215
Makó, V.	305	Najjar, R.	134	Pezzini, A.	813
Malik, A.B.	619	Nam, E.-M.	547	Philippe, A.	643
Malloy, D.J.	1100	Neerman-Arbez, M.	975	Pierli, C.	1138
Malmström, R.E.	157	Neville, C.	100	Pineda, J.	483
Marcenò, R.	233	Newby, A.C.	1006	Pinto, A.	929
Marco, P.	594	Ng, C.H.	852	Piovella, F.	762
Marcucci, R.	521	Nguyen, P.M.	55	Piroth, L.	495
Margarit, E.	977	Nichols, W.L.	178	Plaza, J.	312
Mariño Rodríguez, R.	969	Nicolau, I.	402	Plesch, W.	988
Markakis, S.	541	Nieuwland, R.	1119	Plumb, J.M.	77, 527
Marotti, A.	298	Niles, M.	1091	Plumhoff, E.A.	178
Martínez-González, J.	665	Nishigaki, Y.	963	Poetzsch, B.	325
Marx, G.	1147	Nokes, T.	791	Poggio, R.	596
Marzilli, M.	1138	Nomura, S.	599	Pogliani, E.	233
Marín, F.	483	Nordt, T.K.	1060	Pola, R.	800
Massicotte, M.P.	86	Noventa, F.	789	Poli, D.	367, 938
Massignon, D.	755	Nozawa, Y.	963	Poller, L.	419, 487
Mathioudaki, K.	741	Nugent, D.J.	123	Pomp, E.R.	62
Matsue, K.	1170	O'Shaughnessy, D.	791	Pontara, E.	298
Matsumoto, M.	599	Oestreich, J.H.	217	Prandoni, P.	596
Matsuo, K.	1170	Oguri, M.	963	Preissner, K.T.	1, 610
Matsuo, Y.	599	Oh, D.	547	Prezas, P.	741
Matsusaki, T.	696	Okita, D.K.	834	Prin, L.	577
Matta, F.	134, 1100	Oldenburg, J.	1044	Prins, M.H.	209, 762
Mattsson, C.	1051	Olsen, E.H.N.	818	Prisco, D.	367, 938
Mavridis, K.	373	Omran, H.	325, 1085	Prohászka, Z.	305
May, S.	980	Ordoñez, A.	483	Psyri, A.	541
May, A.E.	682, 911	Orietta Borghi, M.	789	Pyle, M.E.	1078
Mazzone, A.	893	Ott, I.	340	Pötz, O.	911
McKay, H.	178	Ozier, Y.	394	Que, Y.-A.	495
McManus, A.	791	Pacifico, L.	878	Raaz, U.	1163
Mehrad, B.	613	Packard, R.R.S.	983	Raffel, O.C.	535
Meijer, P.	178	Padovani, A.	813	Ramacciotti, E.	748
Meijers, J.C.M.	465	Pagnan, A.	298	Ramírez, L.	570
Mensi, N.	1176	Pai, N.	785	Raskob, G.E.	762
Metoki, N.	963	Paintsil, J.	1104	Rauch, J.	100
Michel, T.	1163	Palareti, G.	487	Reber, G.	789, 988
Micieli, E.	290	Paneesha, S.	791	Reed, G.	878
Middelorp, S.	209, 465	Panova-Noeva, M.	1156	Reh fuss, R.	108
Milani, M.	834	Panzer, S.	333	Reinhart, K.	239
Mirza, B.	1100	Paolini, R.	233	Reinhart, W.H.	720
Miñano, A.	483	Papachristopoulou, G.	381	Reitsma, P.H.	62, 465
Moffat, K.A.	178	Paret, G.	405	Remones, V.	215
Mohri, Y.	599	Park, M.R.	547	Remuzzi, G.	233
Moia M.	487, 596	Parra, R.	570	Reuwer, A.Q.	1119
Molino Lova, R.	521	Parsons, N.	791	Reverter, J.-C.	312
Moll, F.L.	48	Pasterkamp, G.	48	Rezaie, A.R.	513
Molvarec, A.	305	Paulsson, M.	1044	Ribeiro, A.	1128
Mondillo, S.	1138	Peerlinck, K.	185	Ridker, P.M.	351
Monreal, M.	478, 1112	Peeters, W.	48	Riera, A.	478
Monroy-Martínez, V.	916	Pelletier, R.	452	Riess, F.-C.	557
Monteagudo, J.	312	Pengo, V.	410, 789	Rietbrock, S.	527
Montes, J.	1112	Periard, D.	584	Riewald, M.	724
Morath, T.	714	Pernow, J.	157	Righini, M.	886, 1176
Moreillon, P.	495	Perrier, A.	197, 886, 1176	Rigó, Jr. J.	305
Morimatsu, H.	696	Perseghin, P.	233	Rink, M.	1147
Morita, K.	696	Peter, K.	997, 1012	Roberts, C.	487
Mussack, T.	1128	Peters, A.	317	Rodger, M.	886
Myers Jr., D.D.	748	Petersen, L.C.	818	Rodgers, G.M.	806
Mäkelburg, A.B.U.	209	Petrich, B.G.	1020	Rodríguez, C.	665
Mühlenbruch, G.	359			Roldán, V.	483
Müller, C.	1044				
Münch, G.	682				

AUTHORS – Thrombosis and Haemostasis 2009; 101 (1-6)

Romano, M.	687	Seifert, M.	248	Stockschläder, M.	586
Rombouts, E.K.	552	Seifried, E.	1044	Strauss, T.	405
Romualdi, E.	290	Seizer, P.	682, 911	Stridh, M.	601
Rose, P.	778, 791	Seljeflot, I.	601	Strieter, R.M.	613
Rose, A.J.	417	Semeraro, F.	782	Strömqvist Meuzelaar, L.	943
Rosendaal, F.R.	62, 465, 552, 691	Semeraro, N.	782	Stuppia, L.	687
Rosenzweig, N.	405	Seog Kim, B.	547	Sucker, C.	586
Rosing, J.	691	Serebruany, V.	14, 607	Susen, S.	983
Roskell, N.S.	77	Serebruany, V.L.	1041	Suzuki, S.	599, 696
Rossi, A.	284	Settergren, M.	157	Svartberg, J.	471
Rothwell, P.M.	123	Shalito, I.	14	Syed, A.	123
Roussel, B.	1172	Sharifian, R.A.	834	Syrjälä, M.	145
Rubinstein, M.	405	Shbaklo, H.	505	Szlam, F.	827
Rudigoz, R.-C.	755	Sheffield, W.P.	867	Sánchez, A.	977
Ruf, L.	586	Sheptovitsky, V.	840	Sörnmo, L.	601
Ruffatti, A.	789	Shetty, S.	785	Sørensen, B.	563
Ruiz, J.R.	591	Shi, J.	845	Sørensen, B.B.	818
Ruiz-Meana, M.	635	Shi, Q.	902		
Ruiz-Ordaz, B.H.	916	Shiach, C.	487	Tagliaferri, A.	674
Rupprecht, H.-J.	995	Shima, M.	408	Takakura, N.	999
Rusconi, C.P.	827	Shimizu, K.	696	Takeda, T.	408
Ryman, A.	582	Shimizu, M.	599	Takeuch, M.	1170
		Shokri, F.	834	Taliani, M.R.	596
Sadowski, J.	773	Shorr, A.F.	139	Talieri, M.	373, 741
Sakurai, Y.	408	Sibbing, D.	340, 714	Tanaka, K.A.	827
Sala, N.	977	Silingardi, M.	596, 893	Tanaka, M.	963
Sala-Newby, G.B.	1006	Silveira, A.	943	Tanck, M.W.T.	465
Salvi, R.	596	Silverman, S.H.	1032	Tani, M.	696
Samama, C.M.	394	Simmet, T.	682	Tarín, F.	594
Samama, M.	487	Singala, R.	134	Tatlisumak, T.	145
Samama, M.M.	986	Sinha, U.	68	Tatsumi, K.	408
Sanchez, J.-C.	1176	Sitter, T.	1128	Taïeb, A.	582
Santiago, C.	591	Skerka, C.	227	Tchaikowski, S.N.	691
Santilli, F.	220, 687	Skotnicki, A.B.	975	Tebbe, U.	557
Sartorello, F.	298	Smadja, D.M.	983	Ten Cate, H.	1156
Sasaki, G.L.	860	Smith, H.	791	Ten Kate, M.K.	93
Satoh, K.	963	Smith, P.	601	Tepper, O.M.	460
Sauter, M.	1128	Smyth, S.S.	217	Thomadaki, H.	373
Savini, I.	284	Sobel, B.E.	1060	Thomas, A.C.	1006
Scalzulli, P.R.	233	Sofi, F.	521	Tirado, R.	478
Scannapieco, G.	893	Soinne, L.	145	Toda, Y.	696
Scaroni, C.	298	Solymoss, S.	100	Tondeur, S.	787
Schaap, M.C.L.	1119	Soria, C.	212	Tonello, M.	789
Scharf, R.E.	586	Soria, J.M.	483	Torreiro, E.G.	969
Scheller, B.	201	Sorrentino, V.	1138	Toulon, P.	394
Schleussner, E.	248	Sossdorf, M.	239	Touzet, S.	755
Schlitt, A.	1163	Spannag, M.	207	Tripodi, A.	487
Schmitt, M.	222	Spath, B.	1147	Tripp, C.	325
Schneppenheim, R.	239	Speck, U.	201	Trujillo-Santos, J.	478, 1112
Schroeder, T.	586	Spencer, F.A.	878	Tsakiris, D.A.	988
Schubert, S.	1163	Spohn, G.	1044	Turck, N.	1176
Schuepbach, R.A.	724	Spronk, H.M.H.	1156	Turpie, A.G.G.	68, 487
Schulzki, T.	720	Squizzato, A.	31, 290	Tuttolomondo, A.	929
Schumacher, W.A.	108, 780	Stakos, D.	911	Tveit, A.	601
Schurgers, L.J.	359, 706	Stanzel, S.	706	Twickler, M.Th.B.	1119
Schved, J.-F.	787	Steg, P.G.	734	Tässies, D.	312
Schweppe, C.H.	252	Stegherr, J.	714		
Schäfer, K.	991	Stein, P.D.	134, 1100	Udvardy, M.L.	305
Schömig, A.	340, 714	Stein, A.	340, 818	Uitte de Willige, S.	1078
Schürks, M.	351	Steiner, S.	333	Umei, N.	599
Scorilas, A.	373, 381, 541, 741	Steinseifer, U.	1163	Undas, A.	773, 975
Scriven, N.	791	Stellos, K.	682, 911	Urase F.	599
Scroyen, I.	388	Stenger, M.	359	Uszynski, M.	795
Segal, H.C.	123	Stepien, E.	773, 975		
Seidinger, D.	333	Steppich, B.	340	Valdés, M.	478

Valerio, A.	893	Wroblewski, S.K.	748
Valle, B.	591	Wuillemin, W.A.	886
Van Buul, J.D.	649	Wunderlich, F.T.	1044
Van Cott, E.M.	535	Wörnle, M.	1128
Van de Gevel, J.	495		
Van den Besselaar, A.M.H.P.	487	Xi, X.	775
Van der Meer, F.J.M.	487, 552	Xynopoulos, D.	741
Van der Meer, J.	93, 209		
Van Doormaal, F.F.	762	Yaekoub, A.Y.	134, 1100
Van Oerle, R.	1156	Yamada, Y.	963
Van Staa, T.P.	527	Yamakura, M.	1170
Van Tiel, C.M.	1119	Yan, R.	902
Van Vliet, H.A.A.M.	691	Yavin, Y.	422
Van't Hooft, F.	943	Yeal Ahn, J.	547
Vannucci, M.	521	Yegneswaran, S.	55
Vasco, B.	1112	Yoshida, H.	963
Vatish, M.	778	Yoshida, T.	963
Veeger, N.J.G.M.	93, 209	Yoshioka, A.	408
Verde, Z.	591	Young Kim, H.	547
Verdú, J.	594	Yu, H.	845
Vermeer, C.	359, 706	Yuan, Y.	902
Verschuren, F.	1176		
Vestweber, D.	682	Zamlut, M.	1100
Vicente, V.	483	Zaucke, F.	1044
Vidal, F.	570	Zdziarska, J.	975
Vikström, M.	943	Zee, R.Y.L.	351
Vila, M.	402	Zehnder, L.	720
Vogt, W.	714	Zhou, J.	845
Vollenweider, P.	584	Zhou, Z.	1070
Volonghi, I.	813	Zhuang, F.	902
Von Ballmoos, M.W.	460	Zimarino, M.	9
Von Beckerath, N.	340, 714	Zipfel, P.F.	225, 227
Von Elverfeldt, D.	1012	Zirlik, A.	1060
Von zur Muhlen, C.	1012	Zito, M.C.	1138
Vos, H.L.	62, 1078	Zorio, E.	483
Vuilleumier, N.	1176	Zotz, R.B.	586
Vyth-Dreese, F.A.	1025	Zwissler, B.	207
Vázquez López, C.	969		
Völzmann, J.	460		
Wagenvoord, R.	165		
Wakefield, T.W.	748		
Wang, H.	775		
Wang, X.	775		
Wang, Y.	902		
Wang, Z.	902		
Watanabe, S.	963		
Watson, C.A.	108		
Watzka, M.	1044		
Weber, C.F.	207		
Weitz, J.I.	2		
Wells, P.S.	197, 886		
Werdan, K.	1163		
Westenfeld, R.	706		
Wichers, I.M.	465		
Wichmann, H.-E.	317		
Wiedermann, C.J.	696		
Willecke, F.	1060		
Williams, M.D.	139		
Williams, S.A.	123		
Windyga, J.	773		
Wolf, G.	248		
Wolowacz, S.E.	77		
Wong, P.C.	108, 780		
Wright, D.	487		